BRISTOL-MYERS SQUIBB COMPANY Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent of -$27.00 million for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-10-24.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParent · last filed 2012-10-24
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2012-09-30 was -$39.00M, a 150.00% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2012-06-30 was $13.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2012-03-31 was -$1.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for the quarter ending 2011-12-31 was $22.00M, a 100.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2011 was $56.00M, a 460.00% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2010 was $10.00M.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2009 was -$44.00M, a 186.27% decline from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY other comprehensive income (loss), derivatives qualifying as hedges, net of tax, portion attributable to parent for fiscal 2008 was $51.00M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2012-09-30 | -$39.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | -$26.00M derived: sum of 2 quarters · filed 2012-10-24 | -$27.00M 10-Q · filed 2012-10-24 | -$5.00M derived: sum of 4 quarters · filed 2012-10-24 |
| 2012-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $12.00M 10-Q · filed 2012-07-25 | $34.00M derived: sum of 3 quarters · filed 2012-07-25 | $112.00M derived: sum of 4 quarters · filed 2012-10-24 |
| 2012-03-31 | -$1.00M 10-Q · filed 2012-04-26 | $21.00M derived: sum of 2 quarters · filed 2012-04-26 | $99.00M derived: sum of 3 quarters · filed 2012-10-24 | $80.00M derived: sum of 4 quarters · filed 2012-10-24 |
| 2011-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | $100.00M derived: sum of 2 quarters · filed 2012-10-24 | $81.00M derived: sum of 3 quarters · filed 2012-10-24 | $56.00M 10-K · filed 2012-02-17 |
| 2011-09-30 | $78.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $59.00M derived: sum of 2 quarters · filed 2012-10-24 | $34.00M 10-Q · filed 2012-10-24 | $45.00M derived: sum of 4 quarters · filed 2012-10-24 |
| 2011-06-30 | -$19.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | -$44.00M 10-Q · filed 2012-07-25 | -$33.00M derived: sum of 3 quarters · filed 2012-07-25 | -$109.00M derived: sum of 4 quarters · filed 2012-07-25 |
| 2011-03-31 | -$25.00M 10-Q · filed 2012-04-26 | -$14.00M derived: sum of 2 quarters · filed 2012-04-26 | -$90.00M derived: sum of 3 quarters · filed 2012-04-26 | -$54.00M derived: sum of 4 quarters · filed 2012-04-26 |
| 2010-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$65.00M derived: sum of 2 quarters · filed 2012-02-17 | -$29.00M derived: sum of 3 quarters · filed 2012-02-17 | $10.00M 10-K · filed 2012-02-17 |
| 2010-09-30 | -$76.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | -$40.00M derived: sum of 2 quarters · filed 2011-10-27 | -$1.00M 10-Q · filed 2011-10-27 | $35.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-06-30 | $36.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $75.00M 10-Q · filed 2011-07-28 | $111.00M derived: sum of 3 quarters · filed 2012-02-17 | $69.00M derived: sum of 4 quarters · filed 2012-02-17 |
| 2010-03-31 | $39.00M 10-Q · filed 2011-04-28 | $75.00M derived: sum of 2 quarters · filed 2012-02-17 | $33.00M derived: sum of 3 quarters · filed 2012-02-17 | |
| 2009-12-31 | $36.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17 | -$6.00M derived: sum of 2 quarters · filed 2012-02-17 | -$44.00M 10-K · filed 2012-02-17 | |
| 2009-09-30 | -$42.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | -$80.00M 10-Q · filed 2010-10-26 | ||
| 2009-06-30 | -$38.00M 10-Q · filed 2010-07-22 | |||
| 2008-12-31 | $51.00M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |